CD274 and non-small cell lung carcinoma: Thus to some extent, for patients with NSCLC with negative PD‐L1 level, high tumor mutational burden increases the chance of tumor response to immunotherapy (Anagnostou et al., 2017; Rosenberg et al., 2016).